First-ever quality measures aim to reduce diabetes complications

December 12, 2019

WASHINGTON--The Endocrine Society and Avalere Health introduced the first-ever quality measures to help healthcare providers assess how well they identify and care for older adults at greater risk of hypoglycemia--low blood sugar that can be a dangerous complication of diabetes treatment.

A panel of diabetes experts published the quality measures, which focus on outpatient treatment for adults who are 65 and older and have type 2 diabetes, in the Society's Journal of Clinical Endocrinology & Metabolism. The panelists relied on their clinical background, measure development expertise, and insight into patient perspectives to develop the measure set.

"We convened an expert panel of endocrinologists, primary care physicians, diabetes educators, pharmacists, measurement experts and patient advocates to ensure that the quality measures reflect a variety of perspectives and a wide breadth of knowledge on hypoglycemia prevention," said James L. Rosenzweig, MD, of Hebrew SeniorLife in Boston, Mass., who led the expert panel.

An estimated 33 percent of adults aged 65 or older have diabetes, and this age group faces increased risk of developing hypoglycemia. Hypoglycemia can lead to seizures, coma and even death. The U.S. Department of Health and Human Services identified hypoglycemia as one of the top three preventable and measurable adverse drug events.

"Hypoglycemia is an area where we can make meaningful strides in improving diabetes care," said Rosenzweig. "Our research has shown a lack of widespread initiatives to address this issue. These first-of-their-kind quality measures will help clinicians better identify patients who are at risk and combat hypoglycemia."

"Avalere is excited to have been involved in the development of measures focused on older adults who are at risk of having hypoglycemia," said Kristi Mitchell, Practice Director at Avalere Health. "To date, there has been a gap in outpatient measures that screens patients for risk of hypoglycemia and setting tailored targets for this population. We look forward to continuing our work with the Hypoglycemia Prevention Initiative to address this need."

The quality measures outline key risk factors that raise an individual's chances of developing hypoglycemia and emphasize the importance of people who meet these criteria receiving education to help prevent future episodes.

Key risk factors include:The expert panel also recommends healthcare providers capture information about hypoglycemic episodes where individuals experienced altered mental or physical status requiring assistance within the past year. This information can help clinicians better determine if an individual is experiencing growing unawareness of hypoglycemia over time and identify what kinds of interventions stand the best chance of helping the patient avoid future episodes.

Once medical centers and practices begin using the quality measures, the Society and Avalere hope to use information and data from users to refine the quality measures in the future.

Other authors of the report and recommendations include: Paul R. Conlin, MD, of VA Boston Healthcare System in Boston, Mass.; Jasmine D. Gozalvo, PharmD, BCPS, BC-ADM, CDE, LDE, FAADE, of Purdue University in West Lafayette, Ind.; Stephanie B. Kutler, Endocrine Society; Nisa Maruthur, MD, MHS, of Johns Hopkins University in Baltimore, Md.; Penelope Soli, JD, Avalere Health in Washington, D.C.; Sandeep Vijan, MD, of the University of Michigan in Ann Arbor, Mich.; Amish Wallia, MD, of Northwestern University in Chicago, Ill.; and Robin Fein Wright, LCSW, of Diabetes Sisters in Bolingbrook, Ill.

The work on measures was part of a broader quality improvement effort, the Hypoglycemia Prevention Initiative, which was launched by the Endocrine Society and Avalere Health to study how hypoglycemia could be prevented in older individuals with type 2 diabetes and whether primary care physicians could incorporate diagnostic and preventive services into their workflow. The Hypoglycemia Prevention Initiative is supported by Merck & Co., Inc.; Lilly USA, LLC; Novo Nordisk Inc.; Sanofi; and Abbott Diabetes Care Inc.

The manuscript, "2019 Endocrine Society Measure Set for Older Adults with Type 2 Diabetes at Risk for Hypoglycemia," was published online, ahead of print.
About the Endocrine Society

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at Follow us on Twitter at @TheEndoSociety and @EndoMedia.

About Avalere

Avalere Health, an Inovalon Company, is a strategic advisory company whose core purpose is to create innovative solutions to complex healthcare problems. Based in Washington, D.C., the firm delivers actionable insights, product solutions, and custom analytics for leaders in healthcare business and policy. Avalere's experts span 230 staff drawn from Fortune 500 healthcare companies, the federal government (e.g., CMS, OMB, CBO and the Congress), top consultancies and nonprofits. The firm offers deep substance on the full range of healthcare business issues affecting the Fortune 500 healthcare companies. Avalere's focus on strategy is supported by a rigorous, in-house analytic research group that uses public and private data to generate quantitative insight. Through events, publications and interactive programs, Avalere insights are accessible to a broad range of customers. For more information, visit, or follow us on Twitter @avalerehealth.

The Endocrine Society

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to